Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.
iGlarLixi(Insulin Glargine 100 U/ml 和 Lixisenatide)在2型糖尿病(T2D)患者中根據基線 HbA1c 和 BMI 的實際效果。
Diabetes Ther 2024-09-14
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
直接比較固定比例組合的胰高血糖素受體激動劑和基礎胰島素對第2型糖尿病的血糖和非血糖參數的影響。
BMC Endocr Disord 2023-02-06
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
iGlarLixi(胰島素格拉凝100 U/mL 加 利西那酯)在第2型糖尿病患者中根據每日給藥時間的有效性和安全性:來自REALI合併分析的數據。
Diabetes Ther 2023-04-03
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
iGlarLixi(胰島素格拉凝100 U/ml 加 利西塞肽)對於控制不佳的 2 型糖尿病患者具有效性且耐受性良好,年齡無關:REALI 前瞻性實務數據的綜合分析。
Diabetes Obes Metab 2023-05-13
Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.
iGlarLixi在亞得里亞地區國家2型糖尿病患者中的有效性和安全性:ENSURE-ADR,一項真實世界研究。
Diabetes Ther 2023-06-08
Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.
使用 iGlarLixi 治療 2 型糖尿病患者的臨床益處:一項患者層級模擬研究。
Diabetes Ther 2023-08-01
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
在老年人中透過 iGlarLixi 推進第二型糖尿病治療:四項隨機對照試驗的綜合分析。
Diabetes Obes Metab 2024-02-06
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
年齡和疾病持續時間對亞洲2型糖尿病患者使用 iGlarLixi 的療效和安全性的影響:LixiLan-O-AP 和 LixiLan-L-CN 試驗的事後分析。
Diabetes Obes Metab 2024-04-07
Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
成人2型糖尿病患者使用胰島素葡萄糖100單位/毫升加利西塞肽的實際效果和安全性:一項國際、多中心、為期12個月的前瞻性觀察研究。
Diabetes Obes Metab 2024-04-19
Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
從自我測量血糖得出的時間範圍在進入 iGlarLixi 的 2 型糖尿病患者中的應用:三項第 3 期 LixiLan 隨機對照試驗的參與者層級匯總分析。
Diabetes Obes Metab 2024-09-08